var data={"title":"Pentostatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentostatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6372?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentostatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentostatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pentostatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pentostatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709202\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pentostatin should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug toxicities: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of higher doses than those specified is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used pentostatin at higher doses (20 to 50 mg/m2 in divided doses over 5 days) than recommended.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In a clinical investigation in patients with refractory chronic lymphocytic leukemia using pentostatin at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of pentostatin in combination with fludarabine phosphate is not recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182953\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nipent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182954\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nipent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182981\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Purine Analog)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182956\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hairy cell leukemia:</b> IV: 4 mg/m<sup>2</sup> every 2 weeks. <b>Note:</b> The optimal duration has not been determined; in the absence of unacceptable toxicity, may continue until complete response is achieved or until 2 doses after complete response. Discontinue after 6 months if partial or complete response is not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft-versus-host disease (GVHD), steroid-refractory (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial therapy: 1.5 mg/m<sup>2</sup> days 1 to 3 and days 15 to 17 (in combination with corticosteroids) (Alousi, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Steroid-refractory disease: 1.5 mg/m<sup>2</sup> daily for 3 days; may repeat after 2 weeks if needed (Bolanos-Meade, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic graft-versus-host disease (GVHD), steroid-refractory (off-label use):</b> IV: 4 mg/m<sup>2</sup> once every 2 weeks; discontinue after 6 months for sustained objective response, or continue every 2 to 4 weeks for up to 12 months if still improving (Jacobsohn, 2007; Jacobsohn, 2009) <b>or</b> 4 mg/m<sup>2</sup> once every 2 weeks for 3 months (Wolff, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL; off-label use): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Previously treated:</i> 4 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide and rituximab) for 6 cycles (Lamanna, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Previously untreated:</i> 2 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide and rituximab) for 6 cycles (Kay, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous T-cell lymphoma, mycosis fungoides/Sezary syndrome (off-label use):</b> IV: 4 mg/m<sup>2</sup> once weekly for 3 weeks, then every 2 weeks for 6 weeks, then once monthly for a maximum of 6 months (Ho, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>T-cell prolymphocytic leukemia, refractory (off-label use):</b> IV: 4 mg/m<sup>2</sup> once weekly for 4 weeks then every 2 weeks until optimum response is achieved (Mercieca, 1994) <b>or</b> 4 mg/m<sup>2</sup> once weekly for 4 weeks then every 2 weeks (in combination with alemtuzumab) until complete or best response or up to a total of 14 doses (Ravandi, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022818\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pentostatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pentostatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic graft-versus-host disease (GVHD), steroid-refractory:</b> IV: 4 mg/m<sup>2</sup> once every 2 weeks; discontinue after 6 months for sustained objective response, or continue every 2 to 4 weeks for up to 12 months if still improving (Jacobsohn, 2007; Jacobsohn, 2009) <b>or</b> 4 mg/m<sup>2</sup> once every 2 weeks for 3 months (Wolff, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182957\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182958\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; although not adequately studied, two patients with CrCl 50 to 60 mL/minute achieved responses when treated with 2 mg/m<sup>2</sup>/dose. For renal toxicity <i>during</i> treatment, withhold for elevated serum creatinine and determine creatinine clearance. The following adjustments have also been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kintzel, 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 46 to 60 mL/minute: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 31 to 45 mL/minute: Administer 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lathia, 2002:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;60 mL/minute: Administer 4 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 40 to 59 mL/minute: Administer 3 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 20 to 39 mL/minute: Administer 2 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alousi, 2009; Jacobsohn, 2009; Poi, 2013 (for GVHD treatment):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>:  Withhold dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lamanna, 2006 (for previously treated CLL): Serum creatinine &gt;2 mg/dL or 20% above patient&rsquo;s baseline: Withhold treatment until serum creatinine &le;2 mg/dL or returns to baseline, or until CrCl &ge;50 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367853\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20343888\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in pentostatin dosing for hematopoietic stem cell transplant conditioning regimens in adults (Bubalo, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022907\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ANC &lt;200/mm<sup>3</sup> (with baseline ANC &gt;500/mm<sup>3</sup>):  Temporarily interrupt treatment until ANC returns to pre-dose levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS toxicity: Withhold treatment or discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection, active: Interrupt treatment until infection is controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rash: Severe rashes may require treatment interruption or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Other severe adverse reactions: Withhold treatment or discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182935\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nipent: 10 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182921\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182938\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV over 20 to 30 minutes or as a bolus infusion. Hydrate with 500 to 1,000 mL fluid prior to infusion and 500 mL after infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132755\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182936\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Hairy cell leukemia:</b> Treatment (as a single-agent) of untreated and interferon-refractory hairy cell leukemia in patients with active disease (clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744620\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease (treatment); Chronic graft-versus-host disease, steroid-refractory (treatment); Chronic lymphocytic leukemia; Cutaneous T-cell lymphomas, mycosis fungoides/Sezary syndrome; T-cell prolymphocytic leukemia, refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182988\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pentostatin may be confused with pentamidine, pentosan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nipent [U.S., Canada, and multiple international markets] may be confused with Nipin brand name for nifedipine [Italy, Singapore]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182928\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (29% to 42%), pain (8% to 20%), chills (11% to 19%), headache (13% to 17%), central nervous system toxicity (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (26% to 43%), pruritus (10% to 21%), skin changes (4% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;63%), vomiting (&le;63%), diarrhea (15% to 17%), anorexia (13% to 16%), abdominal pain (4% to 16%), stomatitis (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (22% to 60%), anemia (8% to 35%), thrombocytopenia (6% to 32%), bone marrow depression (nadir: 7 days; recovery: 10 to 14 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (2% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (7% to 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (11% to 19%), weakness (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (17% to 20%), upper respiratory tract infection (13% to 16%), rhinitis (10% to 11%), dyspnea (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (42% to 46%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (3% to 10%), facial edema (3% to 10%), hypotension (3% to 10%), peripheral edema (3% to 10%), angina pectoris (&lt;3%), atrioventricular block (&lt;3%), bradycardia (&lt;3%), cardiac arrhythmia (&lt;3%), cardiac failure (&lt;3%), deep vein thrombophlebitis (&lt;3%), hypertension (&lt;3%), localized phlebitis (&lt;3%), pericardial effusion (&lt;3%), sinoatrial arrest (&lt;3%), syncope (&lt;3%), tachycardia (&lt;3%), vasculitis (&lt;3%), ventricular premature contractions (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (3% to 10%), confusion (3% to 10%), depression (3% to 10%), dizziness (3% to 10%), drowsiness (3% to 10%), insomnia (3% to 10%), nervousness (3% to 10%), paresthesia (3% to 10%), abnormal dreams (&lt;3%), abnormality in thinking (&lt;3%), amnesia (&lt;3%), ataxia (&lt;3%), dysarthria (&lt;3%), emotional lability (&lt;3%), encephalitis (&lt;3%), hallucination (&lt;3%), hostility (&lt;3%), meningism (&lt;3%), neuralgia (&lt;3%), neuritis (&lt;3%), neuropathy (&lt;3%), paralysis (&lt;3%), psychoneurosis (&lt;3%), seizure (&lt;3%), twitching (&lt;3%), vertigo (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (8% to 10%), cellulitis (6%), furunculosis (4%), xeroderma (3% to 10%), urticaria (3% to 10%), acne vulgaris (&lt;3%), alopecia (&lt;3%), eczema (&lt;3%), skin photosensitivity (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea (&lt;3%), decreased libido (&lt;3%), hypercalcemia (&lt;3%), hyponatremia (&lt;3%), gout (&lt;3%), loss of libido (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (3% to 10%), flatulence (3% to 10%), gingivitis (3% to 10%), constipation (&lt;3%), dysgeusia (&lt;3%), dysphagia (&lt;3%), glossitis (&lt;3%), intestinal obstruction (&lt;3%), oral candidiasis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%), impotence (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Agranulocytosis (3% to 10%), hemorrhage (3% to 10%), acute leukemia (&lt;3%), aplastic anemia (&lt;3%), hemolytic anemia (&lt;3%), petechia (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (8%), viral infection (&le;8%), bacterial infection (5%), herpes simplex infection (4%), sepsis (3%), abscess (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (3% to 10%), arthritis (&lt;3%), hyperkinesia (&lt;3%), osteomyelitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (4%), amblyopia (&lt;3%), lacrimal dysfunction (&lt;3%), nonreactive pupils (&lt;3%), photophobia (&lt;3%), retinopathy (&lt;3%), visual disturbance (&lt;3%), watery eyes (&lt;3%), xerophthalmia (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Deafness (&lt;3%), labyrinthitis (&lt;3%), otalgia (&lt;3%), tinnitus (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (3% to 10%), nephrolithiasis (&lt;3%), renal disease (&lt;3%), renal failure (&lt;3%), renal function abnormality (&lt;3%), renal insufficiency (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (8% to 10%), sinusitis (6%), pneumonia (5%), asthma (3% to 10%), bronchitis (3%), bronchospasm (&lt;3%), flu-like symptoms (&lt;3%), laryngeal edema (&lt;3%), pulmonary embolism (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dysuria, fungal skin infection, hematuria, lethargy, pulmonary edema, pulmonary toxicity (in combination with fludarabine), uveitis, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182941\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pentostatin or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182925\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Myelosuppression may occur, primarily early in treatment (first few courses). Neutropenia may worsen during initial courses for the treatment of hairy cell leukemia. If severe neutropenia persists beyond early cycles, evaluate for disease status. Monitor blood counts during treatment (more frequently in the initial cycles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: <b>[U.S. Boxed Warnings]: Severe CNS toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. </b>Withhold treatment or discontinue for CNS toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: <b>[U.S. Boxed Warnings]: Severe liver toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.  </b>May cause elevations (usually reversible) in liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary toxicity: <b>[U.S. Boxed Warnings]: Severe pulmonary toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.  Do not administer concurrently with fludarabine; concomitant use has resulted in serious or fatal pulmonary toxicity. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rash: Severe rashes may occur and worsen with therapy continuation; may require treatment interruption or discontinuation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal toxicity: <b>[U.S. Boxed Warnings]: Severe renal toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.</b> Serum creatinine elevations occurring at recommended doses are usually minor and reversible. Withhold treatment for elevated serum creatinine and determine creatinine clearance. May require dosage adjustment or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections: In patients who present with infections prior to treatment, infections should be resolved, if possible, prior to initiation of treatment; preexisting infections may worsen with pentostatin treatment. Treatment should be temporarily withheld for active infections during therapy. Use in patients with infections only if the potential benefit justifies the potential risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;60 mL/minute); the terminal half-life is prolonged; may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Concurrent use with fludarabine has resulted in severe or fatal pulmonary toxicity and is not recommended. Fatal pulmonary edema and hypotension have been reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of a myeloablative regimen for bone marrow transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299851\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182930\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9756&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Pentostatin may enhance the cardiotoxic effect of Cyclophosphamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine: May enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelarabine: Pentostatin may diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegademase Bovine: Pentostatin may diminish the therapeutic effect of Pegademase Bovine. Pegademase Bovine may diminish the therapeutic effect of Pentostatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182943\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Women of childbearing potential should be advised to avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5517182\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pentostatin is excreted in breast milk. Due to the potential for serious adverse reactions in nursing the infant, a decision should be made to discontinue pentostatin or to discontinue breast feeding, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5517303\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count (prior to each dose; more frequently during initial cycles), peripheral blood smears (periodically for hairy cells and to assess treatment response), liver function, serum uric acid, renal function (serum creatinine and/or creatinine clearance at baseline, and serum creatinine prior to each dose), bone marrow evaluation, signs/symptoms of pulmonary and CNS toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182924\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pentostatin is a purine antimetabolite that inhibits adenosine deaminase, preventing the deamination of adenosine to inosine. Accumulation of deoxyadenosine (dAdo) and deoxyadenosine 5&prime;-triphosphate (dATP) results in a reduction of purine metabolism which blocks DNA synthesis and leads to cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182940\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 20 L/m<sup>2</sup> (Lathia, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~6 hours; Renal impairment (CrCl &lt;50 mL/minute): 18 hours (range: 11 to 23 hours [Lathia, 2002])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50% to 96%) within 24 hours (30% to 90% as unchanged drug) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Adults: 68 mL/minute/m<sup>2</sup> (mean) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323197\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nipent Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $2,647.57</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182944\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nipent (BB, BE, DE, ES, FR, GB, GR, IE, IT, KR, NL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19443659\"></a>Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i>. 2009;114(3):511-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19443659/pubmed\" target=\"_blank\" id=\"19443659\">19443659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15837980\"></a>Bolanos-Meade J, Jacobsohn DA, Margolis J, et al, &ldquo;Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo; <i>J Clin Oncol</i>, 2005, 23(12):2661-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/15837980/pubmed\" target=\"_blank\" id=\"15837980\">15837980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2014. <a href=\"http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf</a>. Accessed September 16, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10643542\"></a>Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. <i>Ann Oncol</i>. 1999;10(12):1493-1498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/10643542/pubmed\" target=\"_blank\" id=\"10643542\">10643542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17878478\"></a>Jacobsohn DA, Chen AR, Zahurak M, et al, &ldquo;Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease,&rdquo; <i>J Clin Oncol</i>, 2007, 25(27):4255-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/17878478/pubmed\" target=\"_blank\" id=\"17878478\">17878478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19745067\"></a>Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. <i>Blood</i>. 2009;114(20):4354-4360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19745067/pubmed\" target=\"_blank\" id=\"19745067\">19745067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17008537\"></a>Kay NE, Geyer SM, Call TG, et al. Combination Chemoimmunotherapy With Pentostatin, Cyclophosphamide, and Rituximab Shows Significant Clinical Activity With Low Accompanying Toxicity in Previously Untreated B Chronic Lymphocytic Leukemia. <i>Blood</i>. 2007;109(2):405-411.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/17008537/pubmed\" target=\"_blank\" id=\"17008537\">17008537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16520464\"></a>Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2006;24(10):1575-1581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/16520464/pubmed\" target=\"_blank\" id=\"16520464\">16520464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lathia C, Fleming GF, Meyer M, et al, &ldquo;Pentostatin Pharmacokinetics and Dosing Recommendations in Patients With Mild Renal Impairment,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2002, 50(2):121-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/12172976/pubmed\" target=\"_blank\" id=\"12172976\">12172976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7989933\"></a>Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. <i>J Clin Oncol</i>. 1994;12(12):2588-2593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/7989933/pubmed\" target=\"_blank\" id=\"7989933\">7989933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nipent (pentostatin) [prescribing information]. Lake Forest, IL: Hospira Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poi MJ, Hofmeister CC, Johnston JS, et al. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. <i>Clin Pharmacokinet</i>. 2013;52(8):705-712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/23588536/pubmed\" target=\"_blank\" id=\"23588536\">23588536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19805674\"></a>Ravandi F, Aribi A, O&rsquo;Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. <i>J Clin Oncol</i>. 2009;27(32):5425-5430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19805674/pubmed\" target=\"_blank\" id=\"19805674\">19805674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9756 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709202\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182953\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182954\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F182981\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F182956\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26022818\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F182957\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F182958\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22367853\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20343888\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F26022907\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182935\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F182921\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F182938\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132755\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F182936\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744620\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182988\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182928\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182941\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182925\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299851\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182930\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182943\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5517182\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5517303\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182924\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F182940\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323197\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182944\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9756|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentostatin-patient-drug-information\" class=\"drug drug_patient\">Pentostatin: Patient drug information</a></li><li><a href=\"topic.htm?path=pentostatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Pentostatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}